Generation Bio Co. (GBIO)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

301 BINNEY STREET CAMBRIDGE, MA 02142

Generation Bio Co. operates as a biotechnology company. The Company engages in developing genetic medicines through gene therapy platform for intrinsic hepatic diseases and systemic diseases. Generation Bio serves customers in the United States.

Data as of 2020-10-17
Market Cap1.207 Billion Shares Outstanding46.428 Million Avg 30-day Volume229.229 Thousand
P/E Ratio Dividend Yield EPS-6.28
Price/Sales Price cash flow ratio Price free cash flow ratio-18.3
Book Value6.55 Price to Tangible Book3.97 Alpha0.08
Short Interest Ratio % Short Interest to Float R-squared0.295865
BETA3.33571 52-week High/Low32.18 / 17.0 Stddev0.363384
View SEC Filings from GBIO instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 0 0 (0.0%) No data
Funds Holding: 49 0 20 (1.3%) No data
13F shares: 28.36 Million 0 8.653 Million No data
% Ownership 63.5388 19.3863 No data
New Positions: 48 20 No data
Increased Positions No data
Closed Positions No data
Reduced Positions No data
Total Calls 0 No data
Total Puts 0 No data
PUT/CALL Ratio No data No data
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding GBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GBIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ANGELINO MARK D. CHIEF OPERATING OFFICER

  • Officer
515,483 2020-08-14 1

NORKUNAS MATTHEW CHIEF FINANCIAL OFFICER

  • Officer
0 2020-07-22 2

CHRISTENSEN GUSTAV

  • Director
131,422 2020-06-16 2

RHODES JASON P

  • Director
12,630,758 2020-06-16 2

NICHOLSON DONALD WILLIAM

  • Director
99,076 2020-06-16 2

ROWLAND CHARLES A JR

  • Director
80,627 2020-06-16 2

STEHMAN-BREEN CATHERINE

  • Director
47,523 2020-06-16 2

QUINN ANTHONY G.

  • Director
72,837 2020-06-16 2

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD PARTNERS, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
1,186,215 2020-06-16 1

ZONE HEALTHCARE HOLDINGS, LLC

FARALLON CAPITAL MANAGEMENT LLC

FARALLON PARTNERS L L C/CA

DREYFUSS PHILIP D

FISCH MICHAEL B.

FRIED RICHARD B

KIM DAVID T

LINN MICHAEL G

PATEL RAJIV A

ROBERTS THOMAS G. JR.

  • MEMBER OF GROUP OWNING 10%MANAGER OF ZHH LLCFARALLON GENERAL PARTNERMANAGING MEMBERMANAGING MEMBERMANAGING MEMBERMANAGING MEMBERMANAGING MEMBERMANAGING MEMBERMANAGING MEMBER
5,356,457 2020-06-16 1

SEYBOLD WILLIAM

SPOKES ANDREW J M

WARREN JOHN R.

WEHRLY MARK C

  • MEMBER OF GROUP OWNING 10%MANAGING MEMBERMANAGING MEMBERMANAGING MEMBER
5,356,457 2020-06-16 1

CASDIN CAPITAL, LLC

CASDIN ELI

  • 10% Owner
1,611,215 2020-06-16 1

ATLAS VENTURE FUND X, L.P.

ATLAS VENTURE ASSOCIATES X, LLC

ATLAS VENTURE ASSOCIATES X, L.P.

ATLAS VENTURE OPPORTUNITY FUND I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

  • 10% Owner
12,630,758 2020-06-16 1

MCDONOUGH GEOFF SEE REMARKS

  • Officer
  • Director
  • 10% Owner
1,705,542 2020-06-16 1

INVUS PUBLIC EQUITIES, L.P.

MINNE PASCAL

ARTAL INTERNATIONAL S.C.A.

ARTAL INTERNATIONAL MANAGEMENT S.A.

ARTAL GROUP S.A.

WESTEND S.A.

STICHTING ADMINISTRATIEKANTOOR WESTEND

ARTAL TREASURY LTD

INVUS PUBLIC EQUITIES ADVISORS, LLC

  • 10% Owner
2,814,191 2020-06-16 1

WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

  • 10% Owner
2,112,546 2020-06-16 1

JONAS JEFFREY M

  • Director
0 2020-06-11 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments